Scarica l'app Stockscreener
68.57
0.23%
-0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Dexcom Inc Borsa (DXCM) Ultime notizie
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness Week to Close the Glucose Knowledge Gap - Investegate
DexCom Execs Sued For Allegedly Misleading Growth Claims - Law360
DexCom (NasdaqGS:DXCM) Gains FDA Clearance For Dexcom G7 System - Yahoo Finance
Alert on DexCom from law firm's press release withdrawn - marketscreener.com
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating - MarketScreener
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Resu - GuruFocus
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring - Clinical Advisor
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Results | DXCM Stock News - GuruFocus
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance - MSN
FDA clears Dexcom G7 15 Day - BioWorld MedTech
What to Expect From DexCom's Next Quarterly Earnings Report - Nasdaq
What Does the Market Think About DexCom? - Benzinga
DexCom signals 14% revenue growth target for 2025 with new product launches and expanded coverage - MSN
What To Expect From DexCom's Next Quarterly Earnings Report - Barchart.com
DexCom (DXCM) Faces Market Challenges Amid Strategic Changes - GuruFocus
DexCom (DXCM) Anticipates Growth Driven by Strategic Initiatives - GuruFocus
DexCom (DXCM) Gains on FDA Approval for G7 15 Day Monitoring Sys - GuruFocus
FDA clears Dexcom G7 15-Day continuous glucose monitor - TechTarget
Mizuho Initiates Coverage of DexCom (XTRA:DC4) with Outperform Recommendation - Nasdaq
Dexcom G7 15 Day CGM system cleared by FDA for adults - Investing.com South Africa
Dexcom G7 15 Day CGM System Cleared by FDA - Patient Care Online
DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings ReportHagens Berman - ACCESS Newswire
Dexcom nets FDA clearance for 15-day CGM - MedTech Dive
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomPanhandle - Panhandle - News Channel
Press Release Distribution & PR Platform - ACCESS Newswire
FDA Approves New DexCom Diabetes Device - Yahoo Finance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - Benzinga
Stifel maintains DexCom stock Buy rating, $100 target post FDA nod - Investing.com Australia
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance - Barron's
Dexcom wins FDA nod for 15-day CGM - MassDevice
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - ACCESS Newswire
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction - The Motley Fool
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - Benzinga
DexCom (DXCM) Receives FDA Clearance for Enhanced Glucose Monito - GuruFocus
DexCom Says G7 15 Day Continuous Glucose Monitoring System Gets US FDA Clearance - marketscreener.com
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wea - GuruFocus
Dexcom stock rises on FDA nod for new CGM (DXCM:NASDAQ) - Seeking Alpha
FDA OKs Dexcom G7 15-Day Continuous Glucose Monitor - Medical Product Outsourcing
DexCom shares rise on FDA clearance for new CGM system - Investing.com Australia
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Dexcom
Mizuho Initiates Coverage of DexCom (DXCM) with Outperform Recommendation - Nasdaq
What 6 Analyst Ratings Have To Say About DexCom - Benzinga
Mizuho Initiates DexCom at Outperform With $85 Price Target - marketscreener.com
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
1.45%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):